Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.1 USD | -0.49% | -0.73% | -45.04% |
05-22 | HC Wainwright Adjusts Price Target on ACELYRIN to $18 From $16, Maintains Buy Rating | MT |
05-14 | Acelyrin, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-45.04% | 406M | |
+15.55% | 121B | |
+12.66% | 107B | |
-2.53% | 24.82B | |
+1.14% | 22.48B | |
-9.35% | 18.32B | |
-42.28% | 16.33B | |
-18.92% | 15.31B | |
+6.19% | 14.08B | |
+28.83% | 11.74B |
- Stock Market
- Equities
- SLRN Stock
- News Acelyrin, Inc.
- Acelyrin's Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis Meets Primary Endpoint; Shares Rise